STOCK TITAN

Natera Inc - NTRA STOCK NEWS

Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.

Natera Inc (NASDAQ: NTRA) delivers cutting-edge genetic testing solutions through its proprietary molecular diagnostics platform. This news hub provides investors and healthcare professionals with timely updates on corporate developments, clinical research breakthroughs, and regulatory milestones.

Access official press releases alongside curated analysis of NTRA's innovations in non-invasive prenatal testing, oncology diagnostics, and transplant monitoring. Our repository tracks critical updates including quarterly earnings, partnership announcements, and peer-reviewed study publications.

Key coverage areas include advancements in circulating tumor DNA detection, expansions in reproductive health screening, and financial performance metrics. Bookmark this page to monitor how Natera's bioinformatics expertise continues influencing precision medicine across 150+ countries.

Rhea-AI Summary
Natera submits module for FDA approval of Signatera as a CDx assay for bladder cancer, expects to support future indications and products
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
none
-
Rhea-AI Summary
Natera, Inc. announces three appointments in senior leadership team
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.85%
Tags
none
-
Rhea-AI Summary
Natera announces new study using Signatera to monitor breast cancer patients' response to neoadjuvant therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.21%
Tags
none
Rhea-AI Summary
Natera, Inc. announces pricing of underwritten public offering
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.74%
Tags
none
-
Rhea-AI Summary
Natera, Inc. plans a follow-on public offering of $250 million of common stock, with an option for underwriters to purchase an additional $37.5 million. Morgan Stanley, Goldman Sachs, TD Cowen, and Piper Sandler are acting as joint book-running managers.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.74%
Tags
none
-
Rhea-AI Summary
Natera, Inc. to present at investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.45%
Tags
conferences
Rhea-AI Summary
Natera, Inc. has received confirmation that its Prospera Lung donor-derived cfDNA (dd-cfDNA) transplant assessment test has met coverage requirements from the Centers for Medicare & Medicaid Services’ Molecular Diagnostics Services Program. The test will be covered under Medicare for use in the surveillance setting in lung transplant patients. This is a significant development as lung transplantation has a low survival rate and limited improvement in recipient survival in the past 20 years. Prospera Lung offers a less invasive method of detecting acute rejection and can guide biopsy decision-making and treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
none
-
Rhea-AI Summary
CareDx, Inc. announced that the United States District Court issued an injunction prohibiting Natera from falsely advertising and overstating the scientific performance of its Prospera transplant test. The court upheld the jury's decision that Natera violated the Lanham Act by engaging in false advertising. Natera made nine false advertising claims regarding its Prospera test.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Natera reports Q2 2023 financial results with total revenues of $261.4 million, a 31.9% increase YoY. Product revenues grew 32.7%. Processed 617,200 tests, a 23.5% increase YoY. Achieved favorable results in lawsuits. Raises annual revenue guidance to $1.015 billion - $1.035 billion.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
17.56%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.21%
Tags
conferences
Natera Inc

Nasdaq:NTRA

NTRA Rankings

NTRA Stock Data

20.88B
130.00M
3.45%
93.67%
2.13%
Diagnostics & Research
Services-medical Laboratories
Link
United States
AUSTIN